JGP Global Gestao de Recursos Ltda. acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,233 shares of the biopharmaceutical company’s stock, valued at approximately $300,000. Alnylam Pharmaceuticals makes up approximately 0.4% of JGP Global Gestao de Recursos Ltda.’s portfolio, making the stock its 27th biggest holding.
Several other hedge funds have also recently bought and sold shares of ALNY. Truist Financial Corp acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $474,000. Gilbert & Cook Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 7.7% during the fourth quarter. Gilbert & Cook Inc. now owns 4,443 shares of the biopharmaceutical company’s stock worth $850,000 after purchasing an additional 317 shares during the last quarter. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $71,000. Metis Global Partners LLC grew its holdings in shares of Alnylam Pharmaceuticals by 2.2% during the fourth quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company’s stock worth $839,000 after purchasing an additional 94 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 4.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 438,304 shares of the biopharmaceutical company’s stock worth $83,896,000 after purchasing an additional 19,324 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Alnylam Pharmaceuticals
In other news, CEO Yvonne Greenstreet sold 8,301 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the sale, the chief executive officer now owns 80,534 shares of the company’s stock, valued at $18,602,548.66. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Yvonne Greenstreet sold 8,301 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the sale, the chief executive officer now owns 80,534 shares of the company’s stock, valued at $18,602,548.66. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares in the company, valued at approximately $35,632. The disclosure for this sale can be found here. Insiders have sold a total of 103,148 shares of company stock valued at $25,658,824 over the last 90 days. 1.50% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Trading Down 0.3 %
NASDAQ:ALNY opened at $253.14 on Thursday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $287.55. The business’s 50-day moving average price is $257.19 and its two-hundred day moving average price is $189.87. The firm has a market capitalization of $32.02 billion, a price-to-earnings ratio of -94.46 and a beta of 0.37.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. The company’s revenue for the quarter was up 107.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.21) EPS. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.82 earnings per share for the current year.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Featured Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- CD Calculator: Certificate of Deposit Calculator
- Top 3 Emerging Market ETFs to Watch as the U.S. Dollar Weakens
- Using the MarketBeat Dividend Tax Calculator
- As Home Prices Hit Highs, These Apartment REITs Offer Growth
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 ETFs to Build a Simple and Balanced Stock Portfolio
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.